MentionFox
Home › Executive changes › Cerenome, Inc.
Leadership changes · CNSY · SEC Form 8-K, Item 5.02

Leadership changes at Cerenome, Inc. (2026)

Before you join, sell to or invest in Cerenome, Inc.

MentionFox check on Cerenome, Inc.: no red flags found in 4 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/cerenome

Check Cerenome, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Cerenome, Inc.?

Who joined and who left Cerenome, Inc. (CNSY)? 4 appointments and 1 departure reported from 2026-02-13 to 2026-11-12, each cited to the company's own filing.

Eric Daniels was named Chief Operating Officer of Cerenome, Inc. As of November 14, 2026, Cerenome, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 13, 2026 to November 12, 2026, naming 4 appointments and 1 departure (Form 8-K, November 12, 2026).

CERENOME, INC. named a new Director on Nov 12. 29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

S.H.N. Financial Investments Ltd. also filed stake reports on 20 other companies ↓

Sell to companies like Cerenome, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: In · Person: Ronald A. Andrews · Role: Director · 8-K, 2026-11-12
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-09
  • · In / out: In · Person: Ronald A. Andrews · Role: Director · 8-K, 2026-03-26
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
Changes7
In (appointed)4
Out (departing)1
Latest filing2026-11-12

Cerenome, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-13 to 2026-11-12. They name 3 people, with 4 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Cerenome, Inc. files it.

Also on the record for Cerenome, Inc.

DateRecordFigureOur pageSource
September 18, 2026Form D, private offering$3M soldForm D pageSource
May 15, 2026Stake report, Schedule 13G, by Highbridge Capital Management, LLC7.1% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by CVI Investments, Inc.4.9% of the class5%+ stakesSource
January 22, 2026Stake report, Schedule 13G, by CVI Investments, Inc.6.9% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by S.H.N. Financial Investments Ltd.1.51% of the class5%+ stakesSource
July 29, 2025Stake report, Schedule 13G/A, by Orin Hirschman3.9% of the class5%+ stakesSource

Selling to them or working with them? See who runs Cerenome, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Cerenome, Inc. and the records around it.

Cerenome, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Cerenome, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Cerenome, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Cerenome, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    10 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-11-12InDirector8-K, 2026-11-12
2026-11-12InChief Operating Officer8-K, 2026-11-12
2026-04-09Reportednot named in the filing8-K, 2026-04-09
2026-03-26InDirector8-K, 2026-03-26
2026-03-26In8-K, 2026-03-26
2026-03-26OutDirector8-K, 2026-03-26
2026-02-13Reportednot named in the filing8-K, 2026-02-13

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Cerenome, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Cerenome, Inc.?

New leaders reset buying decisions — get the Full Report on Cerenome, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Cerenome, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Cerenome, Inc., with the record behind each one.

Find candidates like Director at Cerenome, Inc.

Every change, in the filing's words

Filed 2026-11-12 · 8-K

Appointed: Ronald A. Andrews, Director

Prior to his appointment as Chief Business Officer, Mr. Andrews was appointed to our board of directors in March 2026.

Appointed: Eric Daniels, Chief Operating Officer

Mr. Andrews has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K. 1 Appointment of Eric Daniels, M.D., as Chief Operating Officer On November 6, 2026, the Company's board of directors promoted Eric Daniels, M.D., as its Chief Operating Officer.

Also stated in this filing

  • Appointment of Ronald A. Andrews as Chief Business Officer On November 10, 2026, Cerenome, Inc. (the "Company") announced the appointment of Ronald A. Andrews as Chief Business Officer of the Company ("CBO"), effective November 9, 2026.
  • Mr. Andrews, age 67, will be responsible for advancing enterprise growth strategy, strategic partnerships, corporate development, and business opportunities across the Company's diagnostics, therapeutics, and data analytics platforms.
  • Mr. Andrews is also currently serving as Founder, Managing Partner of The Bethesda Group, which is a strategic consulting firm focused on helping organizations in the molecular diagnostic/genomic market segments with strategy, commercial execution, C-suite mentorship and fractional C-suite support.
  • From April 2023 to July 2024, Mr. Andrews served as President and CEO of Twin Strand Biosciences and from July 2016 to December 2022 as President and CEO of Oncocyte Inc. (NASDAQ: OCX).
  • From July 2015 to July 2019 he worked as Founder and Senior Partner of The Bethesda Group and from September 2013 to February 2015 he was President, Genetic Sciences Division, at Thermo Fisher Scientific/ Life Technologies (NASDAQ:TMO).
Filed 2026-04-09 · 8-K

Reported

Appointment of Eric J. Daniels, M.D. as Chief Development Officer On April 9, 2026, Plus Therapeutics, Inc. (the "Company") announced the appointment of Dr. Eric J. Daniels as Chief Development Officer of the Company, effective April 20, 2026.

Also stated in this filing

  • Dr. Daniels, age 53, will be responsible for the development and ultimate approval of the Company's pharmaceutical pipeline effective upon the commencement of his employment with the Company.
  • Prior to joining the Company, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX).
  • In addition, from 2018 through 2021, Dr. Daniels served as the executive director and co-founder of Bayon Therapeutics until it was acquired by Kiora Pharmaceuticals in October 2021 and as chief executive officer of OccuRx Pty Ltd., a clinical stage biotechnology company targeting microvascular disease for ocular indications, from July 2020 through October 2021.
  • Dr. Daniels is also a co-founder and director of Okogen, Inc., a specialty biotechnology development stage ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, since May 2016.
  • Since January 2014, Dr. Daniels has served on the clinical advisory board of Bimini, LLC and was chief medical officer of Bimini from January 2014 to October 2021.
  • From April 2012 to November 2016, Dr. Daniels served as vice president - marketing & sales for Tensys Medical, Inc. (an HBM portfolio company).
Filed 2026-03-26 · 8-K

Appointed: Ronald A. Andrews, Director

Appointment to Board of Directors On March 20, 2026, the Board of Directors (the "Board") of Plus Therapeutics, Inc. (the "Company") unanimously appointed Mr. Ronald A. Andrews to serve as a director of the Board, effective immediately.

Appointed: Ronald A. Andrews

Mr. Andrews was appointed to our Board in March 2026.

Departing: Robert Lenk, Director

Resignation from Board of Directors On March 20, 2026, Robert Lenk resigned as a member of the Board and a member of the Nominating and Corporate Governance Committee.

Also stated in this filing

  • Mr. Andrews is being appointed to the Board to fill the vacancy created by the resignation of Dr. Robert Lenk and is expected to stand for reelection at the Company's 2026 annual meeting of stockholders.
  • The Board has determined that Mr. Andrews satisfies the definition of an "independent director" under the Nasdaq listing standards and the Company's Corporate Governance Guidelines.
  • Mr. Andrews was also appointed to the Nominating and Corporate Governance Committee of the Board.
  • Mr. Andrews is currently serving as Founder, Managing Partner of The Bethesda Group, which is a strategic consulting firm focused on helping organizations in the molecular diagnostic/genomic market segments with strategy, commercial execution, C-suite mentorship and fractional C suite support.
  • From April 2023 to July 2024, Mr. Andrews served as President and CEO of Twin Strand Biosciences, from July 2016 to December 2022 as President and CEO of Oncocyte Inc. (NASDAQ: OCX).
  • From July 2015 to July 2019 he worked as Founder and Senior Partner of The Bethesda Group and from September 2013 to February 2015 he was President, Genetic Sciences Division, at Thermo Fisher Scientific/ Life Technologies (NASDAQ:TMO).
Filed 2026-02-13 · 8-K

Reported

(3) On June 11, 2024, Dr. LaFrance stepped down from his position as the Company's Chief Medical Officer.

Also stated in this filing

  • On January 9, 2026, Plus Therapeutics, Inc. (the "Company") filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the "Registration Statement").
  • On February 9, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025.
  • In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718.
  • (2) This column includes standard benefits, including a 401K match, and health and life insurance premiums.

Tools for this story

Each opens in a new tab, filled in for Cerenome, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cerenome
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Cerenome, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/cerenome